Two Sigma Advisers
PRVB

Two Sigma Advisers’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Two Sigma Advisers’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-74,900
Closed -$792K – 2808
2022
Q4 		$792K Buy
+74,900
New +$604K ﹤0.01% 1682
2021
Q3 		– Sell
-12,900
Closed -$109K – 2756
2021
Q2 		$109K Sell
12,900
-887,500
-99% -$7.16M ﹤0.01% 2337
2021
Q1 		$9.45M Buy
900,400
+328,800
+58% +$4.63M 0.03% 593
2020
Q4 		$9.68M Buy
571,600
+18,900
+3% +$283K 0.03% 580
2020
Q3 		$7.09M Buy
552,700
+477,500
+635% +$6.03M 0.02% 641
2020
Q2 		$1.06M Buy
+75,200
New +$949K ﹤0.01% 1554

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Two Sigma Advisers's PRVB Position: Q1 2023 in Review

Two Sigma Advisers sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 74,900 shares — an estimated $792K sold.

Two Sigma Advisers first reported a position in PRVB in Q2 2020 and held it in 6 quarters. The position peaked at $9.68M in Q4 2020. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Two Sigma Advisers reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 74,900 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $792K.
  • Two Sigma Advisers first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
  • Two Sigma Advisers's Provention Bio, Inc. Common Stock position peaked at $9.68M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.